Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurotrophic Factor Targeting in Oncology and Chronic Pain.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ARTN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ARTN Recombinant Protein (Mature, WT & Variants) HEK293 Expressed (Native Glycosylation), Homodimeric Structure, High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. |
View ARTN Products |
| Gene Delivery | ARTN Premade Lentivirus / Promise-ORF Full-length ORF for stable cell line generation or overexpression. |
View ARTN Products |
| Benchmark Ab | Anti-ARTN Neutralizing Reference Antibody (Sequence of Clinical Clone) Recombinant positive control for binding and neutralization assays. |
View ARTN Products |
| Validator | ARTN siRNA Set For knockdown verification and specificity controls. |
View ARTN Products |
| Co-Receptor | GFRA3 (GFRα3) ECD-Fc Fusion Protein Essential co-receptor for ARTN signaling complex formation. High purity (>95%). |
View GFRA3 Products |
| Receptor | RET (Kinase Domain / Full-length Lentivirus) For downstream signaling validation and kinase assays. |
View RET Products |
| Related Target (Paralog) | GDNF Paralog family member for selectivity counter-screening. |
View GDNF Products |
| Related Target (Paralog) | NRTN (Neurturin) Family member sharing RET receptor, distinct GFRα2 specificity. |
View NRTN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Cysteine-Knot Folding & Homodimer Conformation | HEK293 Expressed (Native Glycosylation & Optimal Disulfide Formation); Endotoxin <1EU/µg; Sequence Verified; Theoretical MW confirmed |
| Cross-Species Cyno/Mouse Evaluation for Toxicology | Human / Mouse / Cyno ARTN ortholog proteins available with >95% purity, sequence verified |
| GDNF Family Selectivity (Avoiding GFRα1/GFRα2 cross-reactivity) | Homolog panel proteins (GDNF, NRTN, PSPN) strictly verified by mass spec for counter-screening |
| Ligand-Receptor Complex Formation (ARTN+GFRα3+RET) | Premixed complex proteins and individual components for SPR/BLI kinetics; GFRA3 & RET Lentivirus for stable cell lines |
| Lack of Functional Cell-Based Assay Controls | Clinical Benchmark Antibodies (Biosimilars) and neutralizing reference Abs included |
| False Positives / Specificity Checks | Validated siRNA included for target-specificity confirmation |
Live ARTN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ARTN therapeutics is intensifying, with major players shifting focus from traditional pain management to oncological applications, particularly in pancreatic ductal adenocarcinoma (PDAC), hormone-resistant breast cancer, and perineural invasion in prostate cancer. As first-generation neutralizing antibodies reach Phase I, the next wave of R&D is targeting bispecific modalities (ARTN/GFRα3), ADC conjugates for tumor-specific delivery, and ligand-level intervention combining with RET kinase inhibitors. In neuropathic pain, ARTN's role in chronic pain, migraine, and osteoarthritis continues to drive interest, though oncology indications are now receiving the majority of preclinical investment. The target remains in a First-in-Class window with strong preclinical rationale across multiple solid tumors and pain conditions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing Antibody | Regeneron, Teva, Early-stage biotech | Osteoarthritis, Chronic Pain, Solid Tumors (PDAC, Breast) | Affinity Validation & Complex Disruption Assay (Need high-purity ARTN + GFRA3 proteins) |
| Bispecific (Anti-ARTN/GFRα3) | Emerging biotech | Oncology | Heterodimer validation (Need cross-reactive Abs and dual target proteins) |
| ADC (ARTN-targeted payload) | Oncology-focused pharma | ARTN-high Cancers (Pancreatic, Prostate) | Internalization assay (Need fluorescently labeled ARTN protein) |
| Decoy Receptor (Soluble GFRα3-Fc) / Small Molecule | Eli Lilly, Pfizer, Protein engineering firms | Chronic Pain, Migraine | Binding affinity comparison (Need ARTN vs. other family members); Selectivity assay (Need off-target GDNF family panel) |